TGFB1 and Alzheimer disease: A particularly noteworthy finding is that when MSCs were exposed to an AD microenvironment, SRGN secreted locally in the Alzheimer's brain was recognized by the MSCs, which were induced to increase the expression of TGF-β, promoting therapeutic efficacy.